Emerging Agents in the Pipeline for Merkel Cell Carcinoma

Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses emerging agents in the pipeline for Merkel cell carcinoma.

Latest Conference Coverage

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

Dr Sabari on Barriers to Biomarker Testing in NSCLC

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512